Physician profile
Ritu Suri
NPI 1972696409
$6,089.68
in general payments reported to CMS, 2019-2025
37 companies · $964 in 2025
The $964 reported for 2025 was more than what 89% of Geriatric Medicine (Family Medicine) providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $765 · 2020: $634 · 2021: $601 · 2022: $697 · 2023: $1,360 · 2024: $1,068 · 2025: $964.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,351 · Education: $41.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,350.66 |
| Education | $41.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $637.64 | 2019-2025 | Kisunla, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $573.76 | 2019-2025 | Farxiga, Breztri, Lokelma |
| Otsuka America Pharmaceutical, INC. | $539.82 | 2020-2025 | Rexulti, Abilify Mycite, Nuedexta |
| Acadia Pharmaceuticals INC | $399.90 | 2019-2023 | Nuplazid |
| Eisai INC. | $326.60 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $308.14 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $295.70 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $259.50 | 2021-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $258.59 | 2019-2025 | Trelegy Ellipta |
| Intra-Sana Laboratories | $188.57 | 2023-2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $175.35 | 2019-2023 | Trulance, Xifaxan |
| Amarin Pharma, INC. | $168.09 | 2020-2022 | |
| Pfizer INC. | $164.69 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $161.18 | 2021-2025 | |
| Amgen INC. | $159.89 | 2023-2025 | Repatha, Evenity |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ritu Suri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.